[SCHEDULE 13G] ProMIS Neurosciences Inc. SEC Filing

Rhea-AI Filing Summary

Ally Bridge Group and affiliates have filed a passive Schedule 13G on ProMIS Neurosciences Inc. (PMN) covering an event date of 29 July 2025. Four related reporting persons—ABG Management Ltd., Ally Bridge Group (NY) LLC, Ally Bridge MedAlpha Master Fund L.P. and Fan Yu—jointly report ownership.

• Shares owned: 6,058,738 common shares held of record by Ally Bridge MedAlpha Master Fund L.P.
• Ownership percentage: 11.8 % of the 51,511,310 shares outstanding (issuer-provided).
• Voting & dispositive power: Sole power – 0; shared power – 6,058,738 for both voting and disposition.
• Warrants: The Fund also holds 9,690,037 additional common shares issuable upon warrant exercise; these are excluded from the reported total because exercise is currently limited.
• Control structure: Fan Yu controls ABG Management Ltd., which is the sole member of Ally Bridge Group (NY) LLC, the manager of the Fund; each party disclaims beneficial ownership except as indirectly attributed.
• Filing type: Schedule 13G (Rule 13d-1[c]) denotes a passive investment with no intent to influence control.

The filing signals a sizeable healthcare-focused institutional stake but does not announce any transaction, operational change or intent to seek control of ProMIS.

Insights

Securities Analyst

TL;DR: Ally Bridge reveals 11.8 % passive stake, adding respected biotech investor to PMN’s cap table.

The disclosure confirms that Ally Bridge MedAlpha Master Fund controls over one-tenth of ProMIS shares, with potential to increase via 9.69 M warrants. Passive 13G status limits activist expectations, yet the size and healthcare specialization of Ally Bridge may improve market perception and float liquidity. Shared voting/dispositive power indicates coordinated management across Cayman, Delaware and Malta entities under Fan Yu. No immediate earnings impact, but the position could influence future financings or secondary sales.

Corporate Governance Expert

TL;DR: Large passive holder emerges; warrants introduce latent dilution risk.

While the group certifies a non-control intent, 11.8 % ownership plus warrants equal to 18.8 % of current outstanding shares confer significant influence potential. Because all voting and dispositive rights are shared, coordination risk exists if strategy changes. The certification under Item 10 reduces immediate governance concerns, yet any future switch to a 13D would signal activism. Investors should monitor warrant exercise thresholds and any amendments that could lift the current limitations.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

ProMIS Neurosciences Inc.

(Name of Issuer)

Common Shares, no par value per share

(Title of Class of Securities)

74346M406

(CUSIP Number)

07/29/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 74346M406

1

Names of Reporting Persons

ABG Management Ltd.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 6,058,738.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 6,058,738.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

6,058,738.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

11.8 %

12

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13G

CUSIP No. 74346M406

1

Names of Reporting Persons

Ally Bridge Group (NY) LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 6,058,738.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 6,058,738.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

6,058,738.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

11.8 %

12

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person: Limited Liability Company

SCHEDULE 13G

CUSIP No. 74346M406

1

Names of Reporting Persons

Ally Bridge MedAlpha Master Fund L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 6,058,738.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 6,058,738.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

6,058,738.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

11.8 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

CUSIP No. 74346M406

1

Names of Reporting Persons

Fan Yu

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

MALTA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 6,058,738.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 6,058,738.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

6,058,738.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

11.8 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: ProMIS Neurosciences Inc.
(b)	Address of issuer's principal executive offices: Suite 200, 1920 Yonge Street, Toronto, A6, M4S 3E2
Item 2.
(a)	Name of person filing: Each of the following is hereinafter individually referred to as a "Reporting Person" and collectively as the "Reporting Persons." This statement is filed on behalf of: ABG Management Ltd. Ally Bridge Group (NY) LLC Ally Bridge MedAlpha Master Fund L.P. Mr. Fan Yu
(b)	Address or principal business office or, if none, residence: The principal business office address for Ally Bridge Group (NY) LLC is 430 Park Avenue, 12th Floor, New York, NY 10022. The principal business office address for ABG Management Ltd. and Mr. Fan Yu is Unit 3902, 39/F, East Tower Cheung Kong Center II, 10 Harcourt Road Central, Hong Kong. The principal business office address for Ally Bridge MedAlpha Master Fund L.P. is c/o Maples Corporate Services Limited, P.O. Box 309, Ugland House, Grand Cayman, Cayman Islands.
(c)	Citizenship: Ally Bridge Group (NY) LLC is organized under the laws of the State of Delaware. Mr. Fan Yu is a citizen of Malta. Each of the other Reporting Persons is organized under the laws of the Cayman Islands.
(d)	Title of class of securities: Common Shares, no par value per share
(e)	CUSIP No.: 74346M406
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: The information contained on the cover pages of this Schedule 13G is incorporated by reference into this Item 4. The ownership information presented herein represents beneficial ownership of the Issuer's common shares, no par value per share ("Common Shares"), based on 51,511,310 Common Shares outstanding as of July 29, 2025, based on information provided by the Issuer. The Common Shares are held of record by Ally Bridge MedAlpha Master Fund L.P. The amount of securities reported herein does not include 9,690,037 Common Shares issuable upon exercise of warrants held of record by Ally Bridge MedAlpha Master Fund L.P., which are subject to limitations on exercise. Mr. Fan Yu is the controlling stockholder of ABG Management Ltd., which is the sole member of Ally Bridge Group (NY) LLC, which manages the investments of Ally Bridge MedAlpha Master Fund L.P. As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the securities held of record by Ally Bridge MedAlpha Master Fund L.P. Each of them disclaims beneficial ownership of such securities.
(b)	Percent of class: 11.8 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 6,058,738
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 6,058,738
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

ABG Management Ltd.

Signature:	By: /s/ Fan Yu
Name/Title:	Fan Yu, Director
Date:	08/04/2025

Ally Bridge Group (NY) LLC

Signature:	By: ABG Management Ltd., its managing member, By: /s/ Fan Yu
Name/Title:	Fan Yu, Director
Date:	08/04/2025

Ally Bridge MedAlpha Master Fund L.P.

Signature:	By: Ally Bridge Group (NY) LLC, its manager, By: ABG Management Ltd., its managing member, By: /s/ Fan Yu
Name/Title:	Fan Yu, Director
Date:	08/04/2025

Fan Yu

Signature:	/s/ Fan Yu
Name/Title:	Fan Yu
Date:	08/04/2025

Exhibit Information

Exhibit 1: Joint Filing Agreement.